Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies
This article presents collaborative positions among excipient manufacturers, drug product manufacturers, and members of the US Pharmacopeia on key issues pertaining to the control of pharmaceutical excipients stemming from a recent Pharmaceutical Quality Research Institute workshop.


Pharmaceutical Technology


For the excipient survey question, approximately 74% of drug-product manufacturers answered few or none for testing excipient suitability using experimental-scale (laboratory scale) drug-product batches or pilot-scale manufacturing batches. This result is not encouraging. Even though the excipient is of compendial quality, not testing the suitability of an excipient(s) procured from new vendors through laboratory- or pilot-scale experiments may be contributing to difficulties currently encountered by drug-product manufacturers during production-batch scale-up operations or when an excipient is procured from different vendor(s).

Survey responses showed that, for USPNF excipients, 88% of excipient manufacturers, 75% of distributors, and 68% of drug-product manufacturers perform additional functionality or processability testing that is not part of any compendial monograph (e.g., USP–NF, PhEur, JP). About three-fourths (76%) of drug-product manufacturer respondents perform such tests to determine excipient suitability for their intended use.

FDA's QbD and CGMPs for the 21st Century initiatives and their anticipated impact on improving pharmaceutical product quality were discussed at the workshop. Workshop participants recognized the value in understanding the physicochemical properties of excipients that impart their functionality in the drug product, as well as their contribution to the successful manufacturing of the product. It was noted that there must be early interaction between the drug-product manufacturer and FDA for QbD-based applications to be successful.

Functionality-related characteristics. Workshop participants noted that IPEC and USP plan to question the need for PhEur to include the tests for functionality-related characteristics (FRCs) in monographs whether nonmandatory or not. Listing nonmandatory FRCs in the monograph may provide misleading guidance and could result in drug-product manufacturers not performing the studies they should to identify the FRCs that matter most in connection with their use of an excipient. It also may increase the possibility of non–value added testing in the supply chain. Recently Pharmeuropa published a proposed General Chapter 5.15, "Functionality-Related Characteristics of Excipients," which explains the use of FRCs in PhEur and how tests may be included in monographs (11). Workshop participants agreed that a general information chapter approach is preferred that does not include the listing of FRCs in monographs.

USP–NF informational chapter ‹1059› "Excipient Performance" provides an overview of the key functional categories of excipients identified in USP–NF along with tests that relate to excipient performance. Careful consideration of the function of the excipient in the dosage form and the critical attributes that relate to excipient performance will determine the need for additional tests on the excipient. The draft of ‹1059› "Excipient Performance" is projected for publication as a Stimuli Article in Pharmacopeial Forum Sept.–Oct. 2007 (PF 33.5). USP's goal is to have the draft available for discussion and feedback. USP emphasizes a distinction in the ‹1059› information chapter tests (focus on performance testing) and those in a monograph (focus on identity, strength, purity, quality). The following text from the most current draft of ‹1059› includes such a statement:
This Informational Chapter provides an overview of the key functional categories of excipients identified in USP–NF along with tests that may relate to excipient performance. This chapter focuses primarily on those tests that are not included as required tests in compendial monographs (e.g., strength, purity, identity). Careful consideration of excipient function, manufacturing process, and dosage form performance will allow for the selection of appropriate tests to assure that critical excipient attributes relating to performance are adequately monitored and controlled.

IPEC foresees a need to continue developing our knowledge and understanding of materials and processes and how they interact to produce medicines that consistently meet the public's expectations (12). The industry should continue to work with compendia to establish a harmonized approach for incorporating physical and chemical tests and analytical procedures in the General Chapters of the pharmacopeias. IPEC does not support the inclusion of these tests into monographs unless they may be needed to fulfill an identification requirement, (e.g., test for viscosity of a polymer). IPEC believes that the selection of appropriate performance-related tests be done by appropriate scientific investigation of the excipients used in a specific formulation in a specific process using specific equipment.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here